Drug Trial Radar · NCT07449741
Phase I Study of HXN6005 in Adult Healthy Participants
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Mar 13, 2027
Study completion Mar 13, 2027
Sponsor
- Lead sponsor
- Helixon Biotechnology (Suzhou) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.
Conditions
- Healthy Volunteers (HV)
Interventions
HXN6005Drug
participants will receive a single subcutaneous dose of HXN6005 at escalating dose levels in Cohort 1-4,
PlaceboDrug
Participants will receive matching placebo across cohorts 1-4 of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to Day 141
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Veritus Research
Bayswater, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.